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epidemiological studies have consistently shown an association between exposure to environmental 
pollutants and diabetes risk in humans. We have previously shown that direct exposure of mouse and 
human islets (endocrine pancreas) to the highly persistent pollutant TCDD (2,3,7,8-tetrachlorodibenzo-
p-dioxin) causes reduced insulin secretion ex vivo. Furthermore, a single high-dose of TCDD (200 µg/kg) 
suppressed both fasting and glucose-induced plasma insulin levels and promoted beta-cell apoptosis 
after 7 days in male mice. The current study investigated the longer-term effects of a single high-dose 
TCDD injection (20 µg/kg) on glucose metabolism and beta cell function in male and female C57Bl/6 
mice. TCDD-exposed males displayed modest fasting hypoglycemia for ~4 weeks post-injection, 
reduced fasting insulin levels for up to 6 weeks, increased insulin sensitivity, decreased beta cell area, 
and increased delta cell area. tcDD-exposed females also had long-term suppressed basal plasma 
insulin levels, and abnormal insulin secretion for up to 6 weeks. Unlike males, TCDD did not impact 
insulin sensitivity or islet composition in females, but did cause transient glucose intolerance 4 weeks 
post-exposure. our results show that a single exposure to dioxin can suppress basal insulin levels long-
term in both sexes, but effects on glucose homeostasis are sex-dependent.
Diabetes mellitus is one of the leading causes of death worldwide, and its prevalence is increasing at alarming 
rates1. Type 2 diabetes (T2D) is the most common form of diabetes, and is characterized by chronic hyperglyce-
mia, peripheral insulin resistance, and insufficient insulin production by pancreatic beta cells2. The rapid increase 
in diabetes incidence worldwide cannot be accounted for by genetics and lifestyle alone, suggesting that other 
environmental factors are likely contributing to diabetes etiology. In particular, epidemiological studies have 
reported an association between exposure to persistent organic pollutants (POPs) and increased diabetes inci-
dence3,4. However, while epidemiological studies can uncover correlative associations, basic research in model 
systems is required to investigate causation.
Generally, POPs are lipophilic chemicals that resist degradation, leading to widespread global dispersion, 
bioaccumulation, and long-term release into the environment5. Dioxins and dioxin-like compounds are a broad 
class of POPs that activate the aryl hydrocarbon receptor (AhR), which induces a variety of target genes, includ-
ing cytochrome P450 (Cyp)1a1 and Cyp1a2. Although CYP enzymes are essential for xenobiotic metabolism, 
CYP-mediated substrate oxidation can also generate highly reactive intermediate metabolites that cause oxidative 
stress and DNA/protein damage6. Our lab has shown that CYP1A enzymes are inducible and functional in human 
and mouse pancreatic islets, and that these enzymes remain active for at least two weeks following a single acute 
exposure to the classic dioxin, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)7. These data indicate that dioxins 
reach the endocrine pancreas in vivo, which may have important implications for islet cell function and survival.
Epidemiological studies have linked serum concentrations of dioxin/dioxin-like chemicals with both 
increased diabetes incidence8–15 and decreased insulin secretion in humans16,17. Suppressed insulin secretion was 
also observed in rodent beta cell lines after direct exposure to organochlorine pesticides and dioxin-like polychlo-
rinated biphenyls (PCBs) in vitro16,18, and in isolated rat and mouse islets 24-hours following in vivo exposure to 
TCDD19. Our lab has also shown that direct exposure of mouse and human islets to TCDD for 48-hours ex vivo 
causes reduced insulin secretion7. Furthermore, a single high-dose injection of TCDD (200 µg/kg) in male mice 
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led to reduced plasma insulin levels for 2 weeks in vivo, and impaired glucose-stimulated insulin secretion by 
isolated islets ex vivo after 1 week7. We also observed a substantial increase in beta cell apoptosis in these mice, 
suggesting that TCDD affects both beta cell function and survival7. However, this high dose of TCDD caused 
significant weight loss and severe hypoglycemia after 2 weeks, which prevented us from assessing longer-term 
metabolic effects of transient TCDD exposure in vivo.
Another limitation of our previous study was that we only examined male mice, similar to other groups18,20–22. 
To our knowledge, there are no published studies investigating whether dioxin exposure leads to sex-specific 
metabolic outcomes in rodents. Interestingly, epidemiological studies suggest a possible sex difference in the 
association between diabetes incidence and serum POP levels. Although studies are contradictory, there is evi-
dence suggesting a stronger association between dioxin exposure and diabetes incidence in women compared 
to men9,11,23. However, there are limited epidemiological studies that investigate sex differences in this context 
and they often lack sufficient power to be conclusive, emphasising the need to further study sex-dependent met-
abolic effects of dioxin exposure in a carefully controlled setting. The purpose of this study was to investigate the 
long-term implications of a single exposure to TCDD on glucose homeostasis and islet cell physiology in male 
and female mice, using a lower dose than in our previous work.
Results
A single dose of tcDD causes a long-term reduction of plasma insulin levels in male mice. To 
examine longer-term effects of acute TCDD exposure on glucose homeostasis we first tested whether the previ-
ously observed decrease in plasma insulin levels following a high dose TCDD injection (200 µg/kg)7 would be 
maintained with a lower dose of TCDD (20 µg/kg) in male mice. Furthermore, it was critical to find a dose that 
did not cause TCDD-induced lethality and wasting syndrome (i.e. severe weight loss and dramatic hypoglyce-
mia)24 so the mice could be maintained long-term (see Fig. 1A for study timeline). Consistent with our previous 
study7, 200 µg/kg TCDD induced a significant decline in body weight and a dramatic decrease in blood glu-
cose levels to ~3 mM within 12 days following exposure (Fig. 1B,C). In contrast, 20 µg/kg TCDD only modestly 
decreased body weight, and fasting blood glucose remained within a normal physiological range throughout the 
study (>6 mM; Fig. 1B,C). During a glucose tolerance test (GTT) at 2 weeks post-injection, mice exposed to 200 
µg/kg TCDD showed severe hypoglycemia (Fig. 1D) and a dramatic decrease in plasma insulin levels (Fig. 1E). 
Interestingly, 20 µg/kg TCDD had no effect on glucose tolerance at either 2 or 4 weeks post-exposure (Fig. 1D,F), 
but significantly reduced plasma insulin levels during the glucose challenge at both time points (Fig. 1E,G). The 
effect of TCDD on insulin secretion was clearly dose-dependent at 2 weeks post-exposure (Fig. 1E). The long-
term suppression of plasma insulin levels in mice exposed to 20 µg/kg TCDD was associated with a significant 
decrease in insulin+ area per islet at 4 weeks (Fig. 1H,I). There was no significant change in glucagon+ area or 
overall islet size (Fig. 1H,I).
We further validated the 20 µg/kg TCDD dosing model by ensuring that TCDD was reaching the endocrine 
pancreas, using Cyp1a1 induction as a biomarker for direct in vivo exposure7. At 2–4 weeks following the 20 µg/
kg or 200 µg/kg TCDD injection, Cyp1a1 expression was induced ~33-fold and ~25-fold, respectively, in the liver 
(Fig. S1A) compared to ~3-fold and ~12-fold, respectively, in the islets (Fig. S1B). Moreover, we also observed a 
dose-dependent effect of TCDD on CYP1A1 enzyme activity in islets (Fig. S1C), indicating that TCDD reaches 
the islets and induces long-term activation of CYP1A1 with both doses. We also verified that 20 µg/kg TCDD 
was not overtly cytotoxic by measuring inflammatory and apoptotic pathways in the liver and islets at 2 weeks 
post-TCDD. Consistent with our previous findings7, we observed an increase in pro-inflammatory cytokines, 
Tnfa and Il-1b, and the anti-apoptotic gene Birc3 in the liver (Fig. S1D), along with a decrease in Il-1b and Birc3 
in the islets (Fig. S1E) at 2 weeks following 200 µg/kg TCDD. The 20 µg/kg TCDD dose caused similar and 
dose-dependent changes in liver inflammation pathways (Fig. S1D), but no changes in islets (Fig. S1E).
TCDD suppresses fasting insulin levels long-term in both males and females, but effects on gly-
cemia, body weight, and insulin tolerance are sex-dependent. We next investigated whether the 
long-term effects of TCDD (using only the 20 µg/kg dose from this point forward) on basal metabolism and fast-
ing insulin levels are sex dependent (see Fig. 2A for study timeline). Consistent with the first cohort (Fig. 1B,C), 
TCDD-exposed male mice showed a sustained decrease in body weight throughout the 6-week study (Fig. 2B,C) 
and reduced fasting blood glucose levels from days 2 to 26 post-injection (Fig. 2D). Male mice also had signifi-
cantly reduced fasting plasma insulin levels at 2, 4, and 6 weeks post-TCDD (Fig. 2E), and a pronounced increase 
in insulin sensitivity at 3 weeks (Fig. 2F). In contrast, female mice only had a transient and very modest decrease 
in body weight (Fig. 2G,H) and fasting blood glucose levels (Fig. 2I) in the first week post-TCDD. Interestingly, 
TCDD-exposed females had significantly reduced plasma insulin levels at 4 and 6 weeks (Fig. 2J), but no overall 
change in insulin sensitivity at 3 weeks (Fig. 2K).
tcDD induces sex-dependent changes in glucose tolerance and insulin secretion. To further 
characterize sex-dependent effects of TCDD exposure on metabolism, we assessed glucose tolerance and beta 
cell function for 6 weeks in vivo after a single TCDD injection. Male mice were modestly hypoglycemic during 
a glucose challenge at 2 weeks post-TCDD compared to controls, but their glycemia was restored by 4 weeks 
(Fig. 3A,B,C). Male mice also showed a significant decrease in plasma insulin levels during GTTs at 2 and 4 weeks 
post-TCDD, with levels returning to normal by 6 weeks (Fig. 3G,H,I). Similar trends were seen in a separate 
cohort of male mice, where plasma insulin levels were suppressed at 1 and 2 weeks post-TCDD but normal by 4 
weeks (Fig. S2A,B,C). Glucose tolerance was also normal in TCDD-exposed males at 4 weeks (Fig. S2D).
In contrast, female mice had normal glucose tolerance at 2 and 6 weeks post-TCDD (Fig. 3D,F), but were sig-
nificantly hyperglycemic during a GTT at 4 weeks post-TCDD (Fig. 3E). Importantly, this transient hyperglyce-
mia at 4 weeks post-TCDD was replicated in a second cohort of female mice (Fig. S2H). TCDD-exposed females 
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showed normal plasma insulin levels during a glucose challenge at 2 weeks post-injection, but had significantly 
decreased insulin levels at 4 and 6 weeks compared to controls (Fig. 3J,K,L). In the second cohort, females were 
transiently hyperinsulinemic at 1 week post-TCDD, followed by reduced insulin levels at 2 weeks, and normal 
levels by 4 weeks (Fig. S2E,F,G).
islet composition is altered in male but not female mice following tcDD exposure. Finally, we 
assessed islet composition to determine whether the decreased beta cell area observed in TCDD-exposed male 
mice (Fig. 1H,I) was reproducible and whether there was sexual dimorphism in beta cell survival. Consistent 
with the first cohort of male mice (Fig. 1H,I), we again observed a modest but significant decrease (~10%) in 
the % insulin+ area per islet in TCDD-exposed males (Fig. 4B,I,J), a trend towards increased % glucagon+ area 
Figure 1. Long-term reduction in plasma insulin levels, but normal glucose tolerance in vivo after a single  
20 µg/kg dose of TCDD in male mice. (A) Schematic summary timeline of the study. Male mice were injected 
with either corn oil, 20 μg/kg TCDD, or 200 μg/kg TCDD on day 0 and followed for up to 4 weeks. BG = blood 
glucose; BW = body weight; GTT = glucose tolerance test; GSIS = glucose-stimulated insulin secretion. (B) 
Body weight and (C) blood glucose levels were measured after a morning fast throughout the study. (D,F) 
Blood glucose and (E,G) plasma insulin levels were measured during an i.p. GTT on day 14 (D,E) and day 
28 (F,G). (H) Average islet area, and % of islet area that is immunoreactive for either insulin or glucagon. (I) 
Representative images of paraffin-embedded pancreas sections on day 28 after exposure to control or TCDD  
(20 μg/kg). Tissues are stained for insulin (red), glucagon (green), and DAPI (blue). Scale bars = 50 μm. All data 
are presented as mean ± SEM. Individual data points on bar graphs represent biological replicates (different 
mice). *p<0.05, **p<0.01 versus control. The following statistical tests were used: (B,C) days −5 to 14, two-
way ANOVA with Dunnett test; day 21 to 28, two-way ANOVA with Sidak test; (D,E) line graphs: two-way RM 
ANOVA with Dunnett test; bar graphs, one-way ANOVA with Dunnett test; (F,G,H) line graphs, two-way RM-
ANOVA with Sidak test; bar graphs, two-tailed unpaired t-test.
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(Fig. 4C,I), a significant increase in % somatostatin+ area (Fig. 4D,J), and no overall change in average islet size 
(Fig. 4A). Interestingly, no changes in endocrine cell composition were observed in the females at 6 weeks after 
TCDD exposure (Fig. 4E–J).
Discussion
This study provides clear evidence that TCDD exposure causes sex-specific metabolic disruption in mice. A 
single exposure to this persistent pollutant suppressed basal insulin levels in both male and female mice for up 
to 6 weeks in vivo, although this was consistently delayed in females compared to males. Additionally, the overall 
impact on metabolism differed drastically between sexes, whereby TCDD-exposed males showed loss of beta 
cell mass, increased insulin sensitivity, weight loss, and hypoglycemia, while females became transiently hyper-
glycemic but had either minimal or no changes to islet composition, insulin sensitivity and body weight. These 
data highlight the need to investigate the link between pollutant exposure and diabetes risk in both sexes, as the 
mechanisms of action are most likely sex-specific.
A significant association between dioxin exposure and diabetes incidence has been reported in numer-
ous epidemiological studies8–13,25–27, but this is not always consistent28–30. For example, diabetes incidence was 
increased in Vietnam veterans12 and the Seveso cohort11 exposed to TCDD and in the Yucheng cohort exposed 
to dioxin-like PCBs9, but there was no significant association between diabetes incidence and serum TCDD 
levels in the NIOSH cohort28. Interestingly, recent studies suggest that other factors, such as obesity and diet, 
may contribute to the association between diabetes and POP exposure, yet are often not considered in epidemio-
logical studies31,32. Additionally, most studies have not reported sex-specific associations between POP exposure 
and diabetes, either because they only included one sex12,25,33,34 or their results were not stratified according to 
sex14,35–38. The few studies that delineated effects by sex have suggested that the link between diabetes incidence 
and POP exposure may be stronger in females than males9,11. For example, in both the TCDD-exposed Seveso 
population and the PCB-exposed Yucheng cohort, the increased risk of diabetes was only seen in females9,11. 
Studies on non-persistent pollutants have also reported sex-dependent effects on diabetes incidence. Air pollution 
(including NO2, particulate matter, and SO2) was associated with an increased risk of diabetes in women but not 
in men39,40, whereas NOX and O3 was associated with diabetes in both men and women, but the association was 
stronger in women41. Based on these studies, we predicted that environmental pollutants would likely disrupt 
metabolism in a sex-dependent manner, and that females may be more susceptible to metabolism-disrupting 
Figure 2. Sex differences in fasting metabolic phenotype and insulin sensitivity following TCDD exposure. (A) 
Schematic summary timeline of the study. (B–F) Male and (G–K) female mice were injected with either corn 
oil or 20 μg/kg TCDD on day 0 and followed for up to 6 weeks. BG = blood glucose; BW = body weight; ITT 
= insulin tolerance test; GTT = glucose tolerance test; GSIS = glucose-stimulated insulin secretion. (B,C,G,H) 
Body weight was measured throughout the study and data are expressed as raw values (B,G), and change in 
body weight relative to the first measurement on day -7 (C,H). (D,I) Blood glucose and (E,J) plasma insulin 
levels were measured after a 4 hour morning fast throughout the study. (F,K) Blood glucose levels during an 
ITT on day 21 (values are normalized relative to time 0 for each mouse). All data are presented as mean ± SEM. 
Individual data points on bar graphs represent biological replicates (different mice). *p<0.05, **p<0.01 versus 
control. The following statistical tests were used: (B–D,G–I) two-way ANOVA with Sidak test; (E,F) bar graphs, 
unpaired two-tailed t-test; (J,K) bar graphs, non-parametric Mann-Whitney test; (F,K) line graphs, two-way 
RM-ANOVA with Sidak test.
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pollutants than males. However, mechanistic studies in a well-controlled model system are clearly required to 
elucidate potential causal effects of pollutants and to better understand sex-specific mechanisms of action.
To investigate causality, we assessed the long-term metabolic impact of transient TCDD exposure in a 
mouse model. We had previously observed that exposure to a single high dose of TCDD (200 µg/kg) reduced 
plasma insulin levels for 2 weeks and caused hypoglycemia in male mice7, effects that were reproduced in the 
current study. These data indicate that TCDD disrupts glucose homeostasis and beta cell function, although 
the hypoglycemia in male mice did not necessarily support our hypothesis of a causal association between 
TCDD and increased diabetes risk. However, TCDD-exposed male mice also had a dramatic 22-fold increase 
in beta cell apoptosis after 1 week7, suggesting that TCDD may have irreversible effects on beta cell mass. In 
this study we opted to use a lower dose of TCDD to allow for longer term metabolic tracking and pancreas 
analysis. Interestingly, 20 µg/kg TCDD suppressed plasma insulin levels in both males and females for up to 6 
weeks, beyond when meaningful levels of TCDD would be expected to remain in the pancreas. For example, only 
~0.03% of a 10 µg/kg TCDD dose remained in the pancreas after 5 weeks in female B6C3F1 mice42. Therefore, we 
speculate that TCDD may have long-lasting effects on beta cell function that persist after the chemical has been 
cleared from pancreas tissue.
Although TCDD-exposed male mice did not develop hyperglycemia in this study (in fact, the opposite 
occurred), the reduction in beta cell mass could be a concern longer term as endogenous beta cell regeneration is 
Figure 3. Transient TCDD exposure leads to long-term suppression of plasma insulin in both sexes, but 
sex differences in glucose tolerance in vivo. (A–C, G–I) Male and (D–F,J–L) female mice were injected with 
either corn oil or 20 μg/kg TCDD on day 0 and glucose tolerance and glucose-stimulated insulin secretion 
were assessed in vivo on days 14, 28, and 42 (see Fig. 2A for schematic timeline). (A–F) Blood glucose levels 
during a GTT on days 14 (A,D), 28 (B,E), and 42 (C,F). (G–L) Plasma insulin levels during the GTT on days 
14 (G,J), 28 (H,K), and 42 (I,L). All data are presented as mean ± SEM. Individual data points on bar graphs 
represent biological replicates (different mice). *p < 0.05, **p < 0.01 versus control. The following statistical 
tests were used: (A–L) line graphs, two-way RM-ANOVA with Sidak test; bar graphs, unpaired two-tailed t-test, 
except for (D) which was analyzed by a non-parametric Mann-Whitney test. See Fig. S2 for additional data from 
a second cohort.
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extremely limited, especially in humans. However, in the 6-week timeframe of this study, male mice compensated 
for insulin insufficiency by increasing insulin sensitivity to maintain glucose homeostasis. In contrast, females did 
not adequately adjust their insulin sensitivity, resulting in transient hyperglycemia coinciding with hypoinsuline-
mia, which is characteristic of diabetes progression. The females returned to normoglycemia roughly when we 
expect the majority of TCDD to have been excreted. Taken together, we predict that an environment with ongoing 
pollutant exposure might be particularly problematic for females, given their impaired metabolic adaptation to 
insulin insufficiency. Our data also suggest that TCDD exposure alone may be insufficient to cause diabetes but 
Figure 4. TCDD exposure decreases % beta cell area and increases % delta cell area in male mice but does 
not affect islet cell composition in female mice. (A–D) Male and (E–H) female mice were injected with 
either corn oil or 20 μg/kg TCDD on day 0 and pancreas tissue was harvested on day 42 for analysis by 
immunofluorescence staining (see Fig. 2A for schematic timeline). (A,E) Average islet area. (B–D,F-H) % of 
islet area that is immunoreactive for insulin (B,F), glucagon (C,G), or somatostatin (D,H). (I–J) Representative 
images of pancreas sections from male and female mice exposed to either corn oil or TCDD showing 
immunofluorescence staining for insulin/glucagon or insulin/somatostatin. Scale bars = 50 μm. All data are 
presented as mean ± SEM. Individual data points on bar graphs represent biological replicates (different mice). 
**p<0.01 versus control; all data was analyzed by unpaired two-tailed t-test.
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could influence diabetes susceptibility in both males and females, at least in part by altering insulin secretion and/
or causing irreversible beta cell death.
The mechanisms underlying TCDD-induced sex differences remain to be investigated but there are several 
possibilities to consider. We noticed that the onset of reduced plasma insulin levels following TCDD exposure 
was consistently delayed in females compared to males. These data suggest that TCDD may be absorbed, dis-
tributed, or metabolised differently in females and males. Unfortunately, there is currently a gap in the literature 
assessing sex dimorphisms in the kinetics of TCDD metabolism, particularly in the pancreas, preventing us from 
further elaborating on the subject. It is also possible that TCDD may interfere with sex hormones, specifically 
estrogen, leading to sex-specific changes in metabolism. Indeed, diabetes prevalence is generally higher in men 
than women, which has been attributed to a protective role of estrogen on body composition and glucose home-
ostasis43. Previous studies have reported crosstalk between AhR and estrogen signaling44, although the role of 
AhR in metabolism is complex and not fully understood45. Whether the TCDD-AhR complex interferes with 
the protective effects of estrogen in our study remains to be investigated but could explain why only female mice 
develop hyperglycemia following TCDD exposure.
It is important to note limitations in our study that may confound the interpretation of our results. First, 
extensive studies have shown that sex-specific sensitivity to dioxins display wide inter- and intraspecies differ-
ences46–49. As such, more studies are required to determine if the sex-specific effects of TCDD on metabolism are 
similar in other strains and species besides C57BL/6 mice. Second, the dose used in this study is not physiolog-
ically relevant to the general population. Human daily intake is approximately 0.3–3.0 pg/kg of body weight50, 
which would be achieved with chronic dosing of ~20 ng/kg TCDD rather than an acute exposure of 20 µg/kg as 
was used in this study. As such this study serves more as a proof-of-principle that TCDD has the potential to affect 
glucose homeostasis and beta cell biology in a sex-dependent manner. We are currently investigating whether 
similar effects are observed following chronic low-dose exposure to TCDD.
Dioxin and dioxin-like pollutants have consistently been associated with an increase in diabetes risk in 
humans3,4. However, research thus far has mainly investigated the acute effects of TCDD on metabolism in male 
rodents. We have shown here that a single transient exposure to TCDD has long-lasting effects on beta cell func-
tion and glucose tolerance in vivo. Furthermore, TCDD has sex-dependent effects on metabolism, whereby only 
male mice experience beta cell loss and only female mice become hyperglycemic following TCDD exposure. 
These results emphasize the need to study the effect of environmental pollutants on metabolism in both sexes 
and that studies in males should not be used to predict the effects of pollutants in females. It will be particularly 
interesting to investigate whether the loss of beta cell mass in males or the transient hyperglycemia observed in 
females after a single high dose of TCDD might progress into overt diabetes with an additional metabolic chal-
lenge. Further research is also required to elucidate the underlying mechanism of dioxin-induced changes in 
metabolism and to determine if these changes occur with a physiologically relevant chronic dosing model.
Methods
Animals. All mice received ad libitum access to a standard irradiated diet (Harlan Laboratories, Teklad Diet 
#2918, Madison, WI) and were maintained on a 12 hour light/dark cycle throughout the study. All experiments 
were approved by the University of British Columbia or Carleton University Animal Care Committees and car-
ried out in accordance with the Canadian Council on Animal Care guidelines.
Cohort 1 (Figs. 1, S1): As outlined in Fig. 1A, 8 week old male C57Bl/6 mice (Jackson Labs) received a single 
i.p. injection of corn oil (25 ml/kg, vehicle control; n = 13), 20 μg/kg TCDD (n = 13), or 200 μg/kg TCDD (n = 
4). Islets were isolated from a subset of mice on days 14 (n = 4 per group) and 28 (n = 4 per group; corn oil and 
20 μg/kg TCDD mice only) for RNA isolation and Cyp1a1 enzyme activity assays. Islets for RNA were stored in 
RLT buffer (Qiagen) at −80 °C. Whole pancreas and liver were harvested from a different subset of mice on day 
28 (n = 5 per group; corn oil and 20 μg/kg TCDD mice only) and stored in 4% paraformaldehyde (PFA) for 24 
hours, followed by long-term storage in 70% ethanol. A piece of liver was also flash frozen in liquid nitrogen and 
stored at −80 °C for RNA isolation.
Cohort 2 (Figs. 2–4): As outlined in Fig. 2A, 8 week old male (n = 12) and female (n = 14) C57Bl/6 mice (bred 
in-house at the Modified Barrier Facility, University of British Columbia) received a single i.p. injection of corn 
oil (25 ml/kg, vehicle control) or 20 μg/kg TCDD. All mice were euthanized on day 42 to harvest pancreas in 4% 
PFA for histological analysis.
Cohort 3 (Fig. S2): Male (n = 10) and female (n = 10) 8 week old C57Bl/6 mice (Charles River) received a sin-
gle i.p. injection of corn oil (25 ml/kg, vehicle control) or 20 μg/kg TCDD. All mice were euthanized after 28 days.
In vivo metabolic assessments. All metabolic analyses were performed in conscious, restrained mice and 
blood samples were collected via saphenous vein using heparinized microhematocrit tubes at the indicated time 
points. Blood glucose levels were measured using a handheld glucometer (Lifescan; Burnaby, Canada).
Body weight and blood glucose levels were assessed weekly or bi-weekly following a 4-hour morning fast. For 
all other metabolic tests, time 0 indicates the blood sample collected after fasting and prior to administration of 
glucose or insulin. For glucose tolerance tests (GTTs), mice received an i.p. bolus of glucose (2 g/kg; Vétoquinol) 
following a 6-hour morning fast. During the GTT, blood was collected at the indicated time points for measuring 
plasma insulin levels by ELISA (ALPCO mouse ultrasensitive insulin ELISA, #80-INSMSU-E01). For insulin tol-
erance tests (ITTs), mice received an i.p. bolus of insulin (0.7 IU/kg, Novolin ge Toronto; Novo Nordisk Canada 
#02024233) after a 4-hour morning fast.
Mouse islet isolation & culture. Islets were isolated from mice by pancreatic duct injection with colla-
genase (1,000 units/ml; Sigma Aldrich #C7657) dissolved in Hanks’ balanced salt solution (HBSS: 137 mM NaCl, 
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5.4 mM KCl, 4.2 mM NaH2PO4, 4.1 mM KH2PO4, 10 mM HEPES, 1 mM MgCl2, 5 mM dextrose, pH 7.2). 
Pancreata were incubated at 37 °C for 12 minutes, vigorously agitated, and the collagenase reaction quenched by 
adding cold HBSS with 1mM CaCl2. The pancreas tissue was washed 3-times in HBSS + CaCl2 (centrifuging for 
1 min at 1000 rpm in between washes) and resuspended in Ham’s F-10 (HyClone #SH30025.01 or Corning #10-
070-CV) containing 0.5% bovine serum albumin (BSA; Sigma-Aldrich #10775835001), 100 units/ml penicillin, 
and 100 μg/ml streptomycin (Corning #30002CI). Pancreas tissue was filtered through a 70 μm cell strainer and 
islets were handpicked under a dissecting scope to>95% purity.
Cytochrome P450 enzyme activity assay. Enzyme activity was measured in isolated mouse islets (50 
islets per well) using the Promega P450-Glo CYP1A1 Assay (#V8752) in 96-well white-walled plates (Greiner 
Bio-One, # 655098) using the lytic method, as described by the manufacturer.
Quantitative real time pcR. RNA was isolated from liver samples using the Qiagen RNeasy Mini Kit 
(#74104) or Trizol Reagent (Invitrogen #15596018), and mouse islets using the Qiagen RNeasy Micro Kit 
(#74004). DNase treatment was performed prior to cDNA synthesis with the iScript gDNA Clear cDNA Synthesis 
Kit (#1725035, Biorad, Mississauga, ON Canada). Quantitative real-time PCR (qPCR) was performed using the 
SsoFast EvaGreen Supermix (#1725200, Biorad) or SsoAdvanced Universal SYBR Green Supermix (#1725271, 
Biorad) and run on a CFX96 or CFX384 (Biorad). Hprt or Ppia was used as the reference gene since these genes 
displayed stable expression under control and treatment conditions. Data were analyzed using the ΔΔCT 
Method. Primer sequences are listed in Table S1.
Immunofluorescent staining and image quantification. Paraffin sections (5 μm thickness) were pre-
pared by the University of Ottawa Heart Institute Histology Core Facility (Ottawa, ON). Immunofluorescent 
staining was performed as previously described7. In brief, slides were deparaffinized with sequential incuba-
tion in xylene and ethanol. Heat-induced epitope retrieval was performed, and slides were incubated with Dako 
Serum Free Protein Block (#X090930–2; Agilent, Santa Clara, CA). Slides were incubated overnight at 4° with 
primary antibodies, and then incubated with secondary antibodies for 1 hr at room temperature. Coverslips were 
mounted with VECTASHIELD HardSet Mounting Medium with DAPI (#H-1500, Vector Laboratories) for coun-
terstaining. The following antibodies were used: rabbit anti-insulin (C27C9, 1:200, Cell Signaling #3014), mouse 
anti-insulin (L6B10, 1:250, Cell Signaling # 8138BF), mouse anti-glucagon (1:1000, Sigma-Aldrich #G2654), 
rabbit anti-somatostatin (1:500, Sigma-Aldrich # HPA019472). For islet quantification, a minimum of 8 islets 
were imaged with an EVOS FL Cell Imaging System (Invitrogen). For each islet, the area was measured for the 
whole islet, insulin+ immunoreactivity, glucagon+ immunoreactivity, and somatostatin+ immunoreactivity using 
ImageJ software. The % hormone+ area was calculated as [(hormone+ area / islet area) × 100], and the average 
value was calculated for each mouse.
Quantification and statistical analysis. All statistics were performed using GraphPad Prism software 
(GraphPad Software Inc., La Jolla, CA). Specific statistical tests are indicated in figures legends. Sample sizes are 
described in Animals and are also shown in schematic timelines (Figs. 1A, 2A). For all analyses, p < 0.05 was con-
sidered statistically significant. Statistically significant outliers were detected by a Grubbs’ test with α = 0.05. All 
data was tested for normality using a Shapiro-Wilk test and for equal variance using either a Brown-Forsyth test 
(for one-way ANOVAs) or an F test (for unpaired t tests). Parametric tests were used for all two-way ANOVAs, 
but normality and equal variance were tested on area under the curve values. Non-parametric statistics was used 
in cases where the data failed normality or equal variance tests. Data are presented as mean ± SEM. Individual 
data points on bar graphs are always biological replicates (i.e. different mice).
Data availability
The datasets generated and/or analyzed during the current study are available from the corresponding author 
upon reasonable request. No applicable resources were generated or analyzed during the current study.
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